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Abstract
Consistent with the excellent clinical results in testicular germ cell tumors (TGCT), most cell lines derived from this cancer
show an exquisite sensitivity to Cisplatin. It is well accepted that the high susceptibility of TGCT cells to apoptosis plays a
central role in this hypersensitive phenotype. The role of the tumor suppressor p53 in this response, however, remains
controversial. Here we show that siRNA-mediated silencing of p53 is sufficient to completely abrogate hypersensitivity not
only to Cisplatin but also to non-genotoxic inducers of p53 such as the Mdm2 antagonist Nutlin-3 and the proteasome
inhibitor Bortezomib. The close relationship between p53 protein levels and induction of apoptosis is lost upon short-term
differentiation, indicating that this predominant pro-apoptotic function of p53 is unique in pluripotent embryonal
carcinoma (EC) cells. RNA interference experiments as well as microarray analysis demonstrated a central role of the pro-
apoptotic p53 target gene NOXA in the p53-dependent apoptotic response of these cells. In conclusion, our data indicate
that the hypersensitivity of TGCT cells is a result of their unique sensitivity to p53 activation. Furthermore, in the very
specific cellular context of germ cell-derived pluripotent EC cells, p53 function appears to be limited to induction of
apoptosis.
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Introduction
TGCT develop from pre-malignant intratubular germ cell
neoplasias and can be histologically classified into seminomas and
non-seminomas. Seminomas consist of sheets of cells with clear
cytoplasm and are relatively homogenous. Non-seminomas include
yolk sac tumors and choriocarcinomas with extraembryonic cell
differentiation, teratomas with somatic cell differentiation, and EC
[1]. Dependent on the histological type, non-seminomas are
composed of a disorganized mixture of differentiated somatic cell
types and extraembryonic cells, together with EC cells. EC cells
represent the pluripotent stem cell compartment in these tumors
and retain their capability for self-renewal as well as differentiation
into multiple cell types. In contrast to most other solid malignancies,
TGCT can be cured at a rate in excess of 80% by Cisplatin-based
chemotherapy regimens even in advanced metastasized phases
[2,3]. These unique response rates have been linked to an intrinsic
hypersensitivity to DNA damaging agents, as observed in several
human EC lines derived from TGCT [4,5]. Various attempts have
been made to understand the molecular mechanisms behind this
hypersensitivity, mostly by comparing Cisplatin-sensitive TGCT
cell lines with Cisplatin-resistant clones established from the same
origin by continuous treatment with increasing doses of Cisplatin.
Mechanisms involved in Cisplatin resistance include reduced drug
uptake, increased drug efflux and increased intracellular detoxifi-
cation [6,7]. Resistance has also been attributed to an enhanced
DNA repair capacity [1]. Cell lines from TGCT have been shown
to express relatively low amounts of the Xeroderma Pigmentosum
group A (XPA) protein, which has been linked to hypersensitivity as
a resultofa reduced NucleotideExcisionRepair(NER)capacity[8–
10]. Exogenous expression of XPA in sensitive TGCT cells,
however, did not reduce sensitivity to Cisplatin in these cells [11].
The unique sensitivity of TGCT cells to Cisplatin has also been
linked to an extensive and rapid induction of apoptosis and to a
reduced ability to induce cell cycle arrest, probably caused by
altered functionality of the p53 pathway in these cells [12]. In
contrast to many other solid tumors, most TGCTs not only harbor
wild type (wt) p53 but also express this tumor suppressor protein in
higher than normal levels [13,14]. The presence of wtp53
overexpression in many TGCT has been proposed as an important
biological explanation for their chemo-sensitivity [15]. However,
studies on the importance of p53 function for Cisplatin hypersen-
sitivity have yielded conflicting results: whereas several in vitro and
in vivo studies have suggested a central role of p53 in the
hypersensitivity of TGCT and embryonic stem cells to Cisplatin
[16–18], others failed to confirm such a role [19,20].
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between p53 protein levels and the extent of apoptosis in
pluripotent TGCT cells. Interestingly, this hypersensitivity to the
pro-apoptotic function of p53 was not limited to DNA damage-
inducing agents, but could also be detected when p53 was
stabilized in a non-genotoxic manner.
Results
Hypersensitivity of EC cells to Cisplatin is p53-dependent
Most cell lines derived from EC undergo apoptosis upon
exposure to very low concentrations of Cisplatin. We first analyzed
whether p53 is essential for Cisplatin-induced apoptosis. To
address this question, we used RNA interference (RNAi) to
specifically knockdown p53 expression. As shown in Figure 1A (left
panel), treatment of NTERA-2D1 cells with p53 siRNA led to a
complete loss of both p53 protein expression and accumulation
upon Cisplatin. Importantly, this RNAi-mediated loss of p53
accumulation was sufficient to completely rescue NTERA-2D1
cells from Cisplatin-induced apoptosis (Figure 1A, middle and
right panels). The same result was observed for the EC cell line
2102EP (Figure S1). In addition, in TGCT cells we found a tight
p53 siRNA dose response relationship for the rescue from
Cisplatin-induced apoptosis, demonstrating that in these cells the
amount of p53 protein is pivotal for their sensitivity to Cisplatin
(Figure 1B).
It has been demonstrated that most TGCTs are characterized
by constitutively high levels of p53 [21,22]. To evaluate if
extraordinarily high p53 levels are responsible for the hypersen-
sitivity we compared p53 protein levels in four wtp53 cell lines
(MCF7, A549, H460, and NTERA-2D1 cells) selected from a
panel of 28 cell lines characterized by different sensitivities to
Cisplatin (Figure 1C, left panel). Neither constitutive p53 protein
levels nor p53 accumulation upon Cisplatin differed significantly
among these cell lines (Figure 1C, right panel). In fact, the two
most resistant cell lines, A549 and MCF7, accumulated even more
p53 upon Cisplatin treatment as compared to the sensitive cell
lines (Figure 1C, right panel). Therefore, hypersensitivity of
NTERA-2D1 cells to Cisplatin does not appear to be due to
exceptionally high levels of p53. This suggests that the specific
cellular context of pluripotent EC cells is what dictates the
predominantly pro-apoptotic function of p53 in these cells.
The PI3 family kinases ATM, ATR, and DNA-PK are
dispensable for p53-dependent induction of apoptosis
upon Cisplatin
We next asked whether DNA damage signaling pathways are
responsible for the preferential activation of the pro-apoptotic
functions of p53 in NTERA-2D1 cells. The major upstream
transducers of DNA damage signaling include ATM, ATR, and
DNA-PK [23]. We therefore examined the roles of these protein
kinases by RNAi experiments. All siRNAs efficiently repressed
their target genes and blocked protein expression (Figure 2A,
upper panel). Surprisingly, neither knockdown of ATM, ATR, or
DNA-PK alone nor ATM/ATR double knockdown or ATM/
ATR/DNA-PK triple knockdown had any significant protective
effect on survival of NTERA-2D1 cells upon Cisplatin. Rather,
triple knockdown of ATM, ATR, and DNA-PK even increased
Cisplatin-induced apoptosis (Figure 2A).
Phosphorylation of serine residues near the N terminus of p53
(in particular serine 15 and 20) by members of the PI3-kinase
family and the CHK family has been reported to be critical for
stabilization of p53 upon DNA damage [24,25]. As expected,
phosphorylation on serine 15 was partially dependent on ATM
and ATR and disappeared almost completely upon ATM/ATR
double or ATM/ATR/DNA-PK triple knockdown (Figure 2B).
p53 phosphorylation on serine 20 was partially affected by ATM,
ATR, or ATM/ATR double knockdown. Triple knockdown of
ATM, ATR, and DNA-PK effectively reduced serine 20
phosphorylation (Figure 2B). Surprisingly, however, we observed
a significant p53 accumulation despite effective knockdown of
these upstream PI3-kinases (Figure 2B). These results indicate that
phosphorylation of p53 on serines 15 and 20 may not be required
for the pro-apoptotic activity of p53 in NTERA-2D1 cells upon
Cisplatin.
Hypersensitivity to Cisplatin depends on concomitant
induction of PUMA and NOXA
To analyze which targets are responsible for the predominant
pro-apoptotic function of p53 in NTERA-2D1 cells, we studied
the expression of a panel of pro-apoptotic and cell cycle regulatory
p53 targets. Cisplatin induced the transcription of p21, FAS/
CD95, PUMA, and NOXA, whereas induction of BAX was only
minimal (Figure 3A). Importantly, p21 transcript levels were found
to be extremely low in NTERA-2D1 cells when compared to
normal fibroblasts or other cell lines and did not lead to
production of detectable p21 protein (Figure S2). PUMA, NOXA,
and FAS expression was completely dependent on p53 since p53
silencing led to an almost complete loss of those factors both
constitutively as well as upon Cisplatin treatment (Figure 3B and
Figure 3C, upper right panel). To test whether PUMA, NOXA, or
FAS play a role in the hypersensitive phenotype of NTERA-2D1
cells, we pre-treated these cells with the corresponding siRNAs. All
siRNAs efficiently repressed their target genes in NTERA-2D1
(Figure 3C, upper panel) and 2102EP cells (Figure S3, upper
panel). Knockdown of PUMA, and to an even greater extent
NOXA, significantly inhibited Cisplatin-induced death of
NTERA-2D1 (Figure 3C, middle and lower panels) and 2102EP
cells (Figure S3, middle and lower panels). Silencing both PUMA
and NOXA almost completely blocked the induction of apoptosis
in NTERA-2D1 cells (Figure 3C, middle and lower panels). In
contrast, FAS knockdown did not change the sensitivity of
NTERA-2D1 (Figure 3C) or 2102EP cells (Figure S3, middle
and lower panels) to Cisplatin. These data indicate that PUMA
and NOXA are the major effectors of p53 in these cells, and p53-
mediated transactivation of both genes is critical for the
hypersensitive phenotype.
NTERA-2D1 cells are hypersensitive to p53 induction
independent of DNA damaging agents
In NTERA-2D1 cells, the p53 protein content is quantitatively
related to Cisplatin sensitivity (Figure 1). In addition, important
DNA damage transducers such as ATM, ATR, and DNA-PK do
not play a major role in Cisplatin hypersensitivity (Figure 2). We
therefore asked whether DNA damage-induced p53 activation is at
all a prerequisite for the hypersensitive phenotype. To that end, we
studied the sensitivity of NTERA-2D1 cells to DNA damage-
independent inducers of p53. It has been demonstrated that
inhibition of Mdm2 function by Nutlin-3 stabilizes p53 in a non-
genotoxic manner [26]. In addition, p53 protein also accumulates
in the absence of DNA damaging agents upon treatment with the
proteasome inhibitor Bortezomib [27]. As shown in Figure 4A (left
panel), p53 accumulation in NTERA-2D1 cells upon Nutlin-3 and
Bortezomib was similar to that seen after Cisplatin. The same
result was also obtained for 2102EP cells (Figure S4A). In contrast
to Cisplatin, neither Nutlin-3 nor Bortezomib elicited comparable
phosphorylation of p53 at serine residues 15 and 20 (not shown),
p53 Mediates Hypersensitivity in TGCT Cells
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19198Figure 1. Hypersensitivity of NTERA-2D1 is entirely dependent on p53. (A) siRNA-mediated knockdown of p53 rescues NTERA-2D1 from
Cisplatin-induced apoptosis. Cells were transfected with siRNA and incubated for 48 h prior to Cisplatin treatment (16 h). Left panel: verification of
p53 knockdown by Western Blot analysis. Middle and right panel: cells were stained with Annexin-V/FITC and PI and analyzed by flow cytometry.
Graph reflects means 6SD of survival after Cisplatin relating to corresponding controls from 5 experiments (P=0.0003). (B) Cisplatin-induced
apoptosis correlates with the amount of p53 protein (densitometric values). Cells were transfected with indicated amounts of p53-targeting siRNA
48 h before Cisplatin treatment (16 h) and analyzed by Western Blot. (C) Hypersensitivity of NTERA-2D1 is not due to extraordinary high levels of p53.
Left panel: Cells were treated with indicated concentrations of Cisplatin to determine IC50 in a panel of 28 cell lines (the two TGCT cell lines NTERA-
2D1 and 2102EP are indicated by open squares) using MTT assay. Three cell lines (MCF-7, A549, H460) with differing Cisplatin sensitivity were chosen
to compare p53 protein levels with NTERA-2D1. Right panel: Cells were treated with Cisplatin for indicated times and whole protein lysates were then
applied to Western Blot analysis. Graph reflects intensity of p53 bands determined by densitometry relating to the amount of GAPDH.
doi:10.1371/journal.pone.0019198.g001
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PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19198Figure 2. ATM, ATR and DNA-PK are dispensable for Cisplatin-induced apoptosis. (A) Prominent upstream kinases of p53 are dispensable
for Cisplatin hypersensitivity of NTERA-2D1 cells. Cells were transfected with siRNA and incubated for 48 h prior to Cisplatin treatment (16 h). Upper
panel: verification of different knockdowns by Western Blot. Middle and lower panel: cells were stained with Annexin-V/FITC and PI and analyzed by
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Importantly, both compounds led to the same rapid and extensive
induction of apoptosis as observed with Cisplatin (Figure 4A; right
panel). Again, apoptosis was dependent on p53, as pretreatment
with p53 siRNA was sufficient to rescue those cells completely
from Nutlin-3 and at least partially from Bortezomib-induced
apoptosis (Figure 4B). The same result was also obtained with
RITA, another inhibitor of the Mdm2-p53 interaction [28] (data
not shown). Again, these data could be confirmed in a second EC
cell line (2102EP; Figure S4B).
In analogy to the results obtained with Cisplatin, Nutlin-3-
induced apoptosis was also correlated with the absolute levels of
p53, as demonstrated by the p53 siRNA dose-response relation-
ship in Figure 4C. These data not only confirm that TGCT cells
are hypersensitive to p53 regardless of how p53 accumulation is
achieved, but also imply that defects in DNA repair are not major
prerequisites for hypersensitivity, since non-genotoxic Mdm2
antagonists or proteasome inhibitors are not expected to inflict
substantial DNA damage. This is further supported by the
demonstration that NTERA-2D1 cells are capable of removing
Cisplatin-DNA adducts when apoptosis is blocked by inhibition of
caspase activation (Figure S5), indicating that a rapid and massive
induction of apoptosis may precede the onset of DNA repair in
embryonal carcinoma cells.
The p53-dependent hypersensitivity of NTERA-2D1 cells
is lost upon short-term differentiation
Pluripotent EC cell lines derived from TGCT such as NTERA-
2D1 can be induced to undergo terminal differentiation along a
neuronal lineage by all-trans-retinoic acid (RA) [29]. We asked
whether the hypersensitivity to p53 is unique to the pluripotent
non-differentiated state or is maintained also upon differentiation.
Indeed, NTERA-2D1 cells lose their hypersensitivity to Cisplatin,
Bortezomib, and Nutlin-3 already after 48 h of RA treatment
(Figure 5A). Because the sensitivity of the non-differentiated cells
depends on p53, we asked whether this predominant pro-apoptotic
p53 response is altered after short-term differentiation. Notably,
pre-treatment of NTERA-2D1 cells with RA did not reduce
constitutive p53 protein levels and had only a minor effect on p53
protein accumulation upon Cisplatin (Figure 5B, left panel). We
therefore sought to determine whether the changes in p53 function
might have been triggered by differences in posttranslational
modifications. As shown in Figure 5B (left panel), Cisplatin-
induced phosphorylation of p53 on serines 15 and 20 was
detectable in both undifferentiated and short-term differentiated
NTERA-2D1 cells, even though it was slightly attenuated in cells
pre-treated with RA. Interestingly, however, Cisplatin-induced
acetylation on lysine 382 was almost completely abrogated after
short-term differentiation (Figure 5B, left panel). To evaluate
whether this reduced acetylation might be the cause for the
observed differential sensitivity to Cisplatin, we pre-treated cells
cultivated in the presence of RA with the histone deacetylase
inhibitor SAHA. Although at concentrations above 2 mM SAHA
completely rescued cisplatin-induced p53 acetylation on lysine
382, it failed to render RA-treated cells hypersensitive to Cisplatin
(Figure 5B, right panel). Hence, differential acetylation on lysine
382 does not seem to play a major role in the reduced sensitivity of
short-term differentiated NTERA-2D1 cells.
To examine changes in p53-regulated gene expression upon
Cisplatin after RA treatment, we performed gene expression
microarray analysis. Out of a total of 161 transcripts defined as
p53-responsive by previously described criteria [30,31], 51 were
changed at least 1.5 fold upon Cisplatin treatment of undifferen-
tiated cells (Figure 5C, left panel; Table S1). Gene ontology
analysis identified 12 of these as apoptosis-related. We compared
these apoptosis-related transcripts in both undifferentiated (con-
trol) and differentiated (RA treated) cells. Interestingly, besides
IER3, NOXA and PUMA were suggested to undergo the most
pronounced reduction upon pre-treatment with RA (Figure 5C,
right panel). Importantly, pre-treatment of NTERA-2D1 cells with
RA not only reduced Cisplatin-induced NOXA but also
constitutive NOXA protein levels whereas Mcl-1 remained
unchanged upon RA (Figure 5D). Furthermore, relative to the
three other wtp53 tumor cell lines analyzed in this study, the non-
differentiated NTERA-2D1 as well as 2102EP cells showed
extraordinary high levels of both constitutive and Cisplatin-
induced NOXA (Figure 5D). These results indicate that NOXA
might play an important role in Cisplatin hypersensitivity of
TGCT cells.
Discussion
Pluripotent TGCT cells are extremely sensitive to apoptotic
stimuli, explaining the excellent clinical results in treatment of
these tumors with Cisplatin-containing drug regimens. Therefore,
understanding the mechanisms underlying this hypersensitivity
may open the road to manipulate other tumor types in order to
enhance the therapeutic index of cytotoxic therapy. Analysis of
various potential mechanisms, including altered drug transport,
detoxification mechanisms and DNA repair [32], did not
unequivocally identify the critical cause of the extraordinary
sensitivity of TGCT cells. We found that p53 is required for the
hypersensitive phenotype in these cells: (i) silencing of p53
abrogates hypersensitivity in cell lines derived from TGCTs, (ii)
the absolute level of p53 protein upon Cisplatin treatment
determines the extent of apoptosis in these cells, and iii) the
hypersensitive biological response to p53 is not limited to DNA
damage-induced activation of this tumor suppressor protein.
Furthermore, our data demonstrate for the first time that in these
cells the p53 targets NOXA and PUMA are important effectors of
this predominant pro-apoptotic function whereas the p53
upstream kinases ATM, ATR, and DNA-PK are dispensable.
A pivotal role of p53 in TGCT hypersensitivity has been
implicated many years ago. Thus, it was noted that TGCTs rarely
contain p53 mutations [13,14], but TGCT patients who did not
respond to chemotherapy could be linked to tumors with mutated
p53 [33]. In addition, high levels of wtp53 protein were detected
by immunohistochemistry in TGCT [21], and constitutively high
levels of p53 were also detected in many cell lines derived from
TGCT [22,34]. Lutzker et al. found that, in isogenic mouse
teratocarinoma cells, a higher rate of DNA damage-induced
apoptosis correlated with higher basal levels of exogenous p53
[16]. Therefore, it has been postulated that high p53 protein
content with latent transcriptional activity may be the prerequisite
for the rapid activation of p53 and the concomitant loss of viability
following DNA damage in these cells. Our data demonstrate that
flow cytometry. Graph reflects means 6SD of survival after Cisplatin relating to corresponding controls (cells treated with the same siRNA but
cultivated in absence of Cisplatin) from 3 experiments. (B) Phosphorylation on serines 15 and 20 does not seem to be a requirement for p53
accumulation in NTERA-2D1 cells upon Cisplatin. Knockdowns described in (A) cultivated in presence or absence of Cisplatin were analyzed for
posttranslational modifications and amount of p53 protein by Western Blot.
doi:10.1371/journal.pone.0019198.g002
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e19198hypersensitivity depends on induction of p53 but does not
necessarily require extraordinary high levels. By comparing p53
among different tumor cell lines we found that both constitutive as
well as Cisplatin-induced p53 levels were actually even lower in
the most sensitive cell line, NTERA-2D1, when compared to
resistant cell lines. These results are in line with findings from
Kersemaekers et al., who compared p53 levels of seminomas and
non-seminomas with normal testis as well as breast and colon
cancer cell lines, and found relatively low amounts of p53 in
TGCT cells [19].
Whereas most investigators came to the conclusion that p53 is
required for the extreme sensitive phenotype of TGCT cells, some
studies have failed to support a predominant role of p53. Burger et
al. compared NTERA-2D1 cells (harboring wtp53) with NCCIT
Figure 3. NOXA and PUMA mediate Cisplatin-induced apoptosis downstream of p53. (A) Cisplatin induces p21, FAS, NOXA and PUMA.
Cells were treated with Cisplatin for 8 h. RNA was extracted and transcribed to cDNA. Expression of selected p53 target genes was determined by
PCR. Graphs reflect means 6SD from 3 experiments of mRNA levels normalized to GAPDH (*: P,0.05). (B) Constitutive and Cisplatin induced NOXA
and PUMA protein levels depend on p53. Cells were transfected with control siRNA or p53 siRNA and incubated for 48 h prior to Cisplatin treatment
(16 h). Efficacy of p53 silencing as well as expression of PUMA and NOXA protein were then analyzed by Western Blot. (C) NOXA and PUMA are
important mediators of Cisplatin-induced apoptosis. Cells were transfected with siRNA and incubated for 48 h prior to Cisplatin treatment (16 h).
Upper panel: validation of siRNA efficacy by Western Blot (for NOXA and PUMA; upper left panels) or by evaluation of surface expression using a
CD95/FAS specific antibody conjugated to FITC and flow cytometry (for FAS; upper right panel; *: P,0.05). Lower panel: cell survival upon Cisplatin
treatment. Cells were stained with Annexin-V/FITC and PI and analyzed by flow cytometry. Graph reflects means 6SD of survival after Cisplatin
relating to corresponding controls from 3 experiments (*: P,0.05).
doi:10.1371/journal.pone.0019198.g003
Figure 4. NTERA-2D1 cells are hypersensitive to pro-apoptotic functions of p53 independent of DNA damage. (A) Hypersensitivity of
NTERA-2D1 cells is also observed upon DNA damage-independent accumulation of p53. Cells were treated with Cisplatin, Nutlin-3, or Bortezomib,
respectively for indicated times and p53 protein was analyzed by Western Blot (left panel). In addition, cells treated for 24 h were stained with
Annexin-V/FITC and PI and analyzed by flow cytometry (right panel). (B) Apoptosis upon the non-genotoxic agents Nutlin-3 and Bortezomib is
dependent on p53. Cells were transfected with siRNA and cultivated for 48 h prior to Nutlin-3 or Bortezomib treatment (16 h). Cells were stained with
Annexin-V/FITC and PI and analyzed by flow cytometry. Graph reflects means 6SD of survival after Cisplatin relating to corresponding controls from 3
experiments (P=0.0003 and P=0.0014 for Nutlin-3 and Bortezomib, respectively). (C) Nutlin-3 induced apoptosis directly correlates with the amount
of p53 protein (determined by densitometry). Cells were transfected with indicated amounts of p53-targeting siRNA 48 h before Nutlin-3 treatment
and analyzed by Western Blot.
doi:10.1371/journal.pone.0019198.g004
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PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e19198Figure 5. Short-term differentiation of NTERA-2D1 by RA causes a loss in hypersensitivity. Cells were partially differentiated with RA for
48 h prior to drug treatment. (A) Short-term differentiation rescues NTERA-2D1 from cell death induced by DNA damaging and DNA damaging
independent agents. Cells were treated with Cisplatin, Nutlin-3 or Bortezomib, respectively for 16 h, stained with Annexin-V/FITC and PI and analyzed
by flow cytometry. (B) Posttranslational modifications seem to play a minor role in loss of hypersensitivity upon short-term differentiation. Left panel:
differentiated and control cells were treated with Cisplatin for indicated times and analyzed by Western Blot. Right panel: upon differentiation with
RA, cells were pre-incubated with indicated concentrations of histone deacetylase inhibitor SAHA for 2 h followed by Cisplatin treatment. Cells were
stained with Annexin-V/FITC and PI and analyzed by flow cytometry and protein levels of p53 and acetylation on lysine 382 were analyzed by Western
Blot. (C) Expression level of NOXA upon Cisplatin is reduced in NTERA-2D1 cells pre-treated with RA. Differentiated and control cells were treated with
Cisplatin for 6 h, RNA was isolated and applied to microarray analysis to assess global gene expression. Left panel: selection criteria for Cisplatin-
induced p53 target genes related to apoptosis. Right panel: expression levels of the 12 apoptosis-related p53 targets upon Cisplatin were compared
to cells differentiated prior to Cisplatin treatment. Graph reflects means 6SD from 3 experiments. (D) NOXA basal and Cisplatin-induced protein levels
p53 Mediates Hypersensitivity in TGCT Cells
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Cisplatin between these cell lines [35]. However, different cell lines
not only differ in their p53 status but also in many other factors
important for induction of DNA damage-induced apoptosis,
making it difficult to draw any conclusion basing on such
univariate analysis. For example, it has been demonstrated
recently that defective ATM or CHK2 signaling renders p53-
deficient tumor cells hypersensitive to Cisplatin, whereas the same
defects had the opposite effect in tumor cells harboring wtp53
[36]. More direct evidence that p53 may be dispensable for
sensitivity to Cisplatin in TGCT cells came from Burger et al.:
partial inactivation of p53 by HPV16-E6 in NTERA-2D1 cells did
not render these cells more sensitive to Cisplatin [20]. HPV16-E6,
however, may also alter other DNA damage response pathways
independent of its ability to target p53 for degradation, including
the WNT pathway [37]. Using very specific RNAi-mediated
silencing of p53, we and others [17] found that inhibition of p53
accumulation dramatically reduces Cisplatin sensitivity. Moreover,
our data for the first time demonstrate a linear correlation between
the amounts of apoptosis upon Cisplatin with the absolute level of
accumulated p53.
p53 accumulation upon DNA damage is regulated by
posttranslational modifications at the N terminus of the protein,
in particular phosphorylation on serines 15 and 20, mediated
principally by the DNA damage transducers ATM, ATR, and
DNA-PK [24,25]. Interestingly, RNAi-mediated downregulation
of ATM, ATR, and DNA-PK did not prevent Cisplatin-induced
p53 accumulation and subsequent induction of rapid and massive
apoptosis in NTERA-2D1 cells. These data demonstrate that
neither activation of these PI3K family members nor phosphor-
ylation of p53 on serines 15 and 20 are required for
hypersensitivity to Cisplatin in these cells. This is in line with
our findings that the high sensitivity to p53-dependent apoptosis in
pluripotent TGCT cells is not necessarily dependent on DNA
damage. Thus, we found a comparable hypersensitivity in cells
treated with non-genotoxic p53 inducers such as inhibitors of the
Mdm2-p53 interaction. In analogy to the results obtained with
Cisplatin, Nutlin-3-induced apoptosis in NTERA-2D1 cells was
also highly related to the absolute levels of accumulated p53
protein. In concordance with these results, two recently published
studies showed a high sensitivity of TGCT cells to Nutlin-3
[38,39]. In addition, both TGCT cell lines tested in our study
responded to the proteasome inhibitor Bortezomib with p53
accumulation and concomitant rapid induction of apoptosis. The
role of p53 in proteasome inhibitor-induced cell death is far more
controversial. E.g. it has been demonstrated that Bortezomib
induces apoptosis in lymphoma and melanoma cells via stabiliza-
tion of NOXA protein independently of p53 [40,41]. However,
the RNAi experiments performed in the present study clearly
demonstrate an important role of p53 for Bortezomib sensitivity in
TGCT cells. Although cell death could not be completely blocked,
p53 silencing significantly reduced Bortezomib-induced apoptosis
in both cell lines tested. These data also support previous reports
on the role of p53 for proteasome inhibition-induced cell death
[42,43].
Together, these data indicate that in embryonal TGCT cells
elevation of p53 protein levels is sufficient to induce apoptosis,
regardless of how p53 accumulation is achieved. Therefore,
therapy regimens including non-genotoxic Mdm2 or proteasome
inhibitors may be as effective as cytotoxic therapies for treatment
of TGCT with wtp53 status, thus avoiding the relatively marked
side effects of Cisplatin such as nephrotoxicity and neurotoxicity
[44,45].
These findings also suggest that DNA repair deficiency may not
be a prerequisite for hypersensitivity in these cells since DNA
damage is not expected to be substantially induced by non-
genotoxic agents. The view that defects in the DNA repair
machinery are not critical prerequisites for hypersensitivity is
further supported by our finding that NTERA-2D1 cells are
capable of removing Cisplatin adducts from the DNA when
apoptosis is transiently blocked by caspase inhibition (supplemen-
tary Figure S2). Therefore, the reduced repair capacity observed in
TGCT cells may be related to an extremely rapid and effective
apoptosis preceding the onset of DNA repair.
The exact molecular mechanisms of how p53 distinguishes
between pro-apoptotic and cell cycle regulating target genes still
remain unclear. The function of p53 and its promoter binding
capacity is regulated by a number of posttranslational modifica-
tions but also by various cofactors [46,47] and is therefore largely
dependent on the cellular context. Our data indicate that in the
particular cellular background of EC cells p53 seems to act
primarily as a pro-apoptotic factor. This is in line with the view
that in TGCT p53 might predominantly transactivate pro-
apoptotic targets whereas the products of cell cycle regulatory
genes such as p21 are almost completely absent upon Cisplatin
[21,48,49]. In accordance with previous findings [17], our results
show that p53 is able to transactivate p21 in TGCT cells upon
Cisplatin. However, the absolute p21 transcript levels of the
treated cells were far below those of normal control cells and did
not lead to a detectable induction of p21 protein. Interestingly, the
opposite was true for the pro-apoptotic BH3-only protein NOXA.
We found that both constitutive and Cisplatin-induced NOXA
expression is significantly higher in NTERA-2D1 and 2102EP
cells compared to other cell lines. The predominant role of NOXA
in the sensitivity of EC cells to Cisplatin is demonstrated by the
observation that silencing of NOXA rendered those cells
significantly more resistant. The same effect, albeit less pro-
nounced, was seen for PUMA. In our TGCT model, combined
silencing of NOXA and PUMA had additive effects and almost
completely rescued NTERA-2D1 cells from Cisplatin-induced
apoptosis, indicating that the pro-apoptotic function of p53 is
predominantly mediated by induction of NOXA and PUMA.
Interestingly, a synergistic induction of apoptosis by NOXA and
PUMA has also been reported for HeLa and MEF cells [50]. In
contrast to NOXA and PUMA, silencing of FAS/CD95 had no
effect on Cisplatin-induced apoptosis in NTERA-2D1 cells,
despite an effective induction of its expression, indicating that
the CD95 apoptotic pathway is not relevant for hypersensitivity to
Cisplatin in these cells.
NTERA-2D1 are highly malignant EC cells, which have
retained their pluripotent stem cell properties [51] but can be
induced to differentiate and thereby lose their tumorigenicity by
treatment with RA [29]. We found that hypersensitivity to
Cisplatin in NTERA-2D1 cells is lost already upon short-term
treatment with RA. Therefore, this cell model seems to perfectly
reflect the in vivo situation, since differentiation and loss of
embryonic features as observed in mature teratomas is also
accompanied by reduced chemosensitivity [1,52]. Our results
suggest that an altered p53 activity may directly be involved in this
loss of sensitivity upon differentiation. This is supported by the
are higher in non-differentiated NTERA-2D1 and 2102EP cells than those of differentiated NTERA-2D1 (NTERA-RA) or other tumor cell lines. Cells were
treated with Cisplatin for 16 h and harvested. Lysates were then used for Western Blot analysis.
doi:10.1371/journal.pone.0019198.g005
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from Cisplatin but also from apoptosis mediated by the non-
genotoxic p53 inducers Nutlin-3, RITA, and Bortezomib. In
addition, microarray analysis uncovered Cisplatin-induced p53
target genes differentially expressed in cells pre-treated with RA.
Interestingly, one of the most pronounced differences was observed
for NOXA, which was significantly reduced upon treatment with
RA. This indicates again a prominent role of this BH3-only protein
in the hypersensitivity of pluripotent TGCT cells.
In sum, our data indicate that hypersensitivity of TGCT is a
result of their unique sensitivity to the pro-apoptotic effects of p53,
which is lost upon differentiation. Furthermore, in this very
specific cellular context of pluripotent germ cell-derived EC cells,
p53 function appears to be limited to induction of apoptosis.
Materials and Methods
Cell culture
MCF-7, A549, and H460 cells were obtained from the NCI-60
cell panel. 2102EP cells were procured from the American Type
Culture Collection (ATCC). NTERA cells were obtained from
LGC Standards, Germany. Cells were cultivated in RPMI-1640
(Biochrom, Germany) with 10% FCS and glutamine. For short-
term differentiation NTERA cells were treated with 10 mM retinoic
acid (Sigma, Germany) for 48 h prior to experimental procedures.
Reagents
Cisplatin was used at a concentration of 10 mM. Generally, cells
were pre-incubated with inhibitors for 2 h prior to Cisplatin
treatment to ensure complete target inhibition at this time point.
zVADfmk (Bachem, Germany) was used at 50 mM. Nutlin-3
(Sigma, Germany) was used at 10 mM. Bortezomib (Research
Chemicals, Canada) was used at 10 nM. SAHA (Biomol,
Germany) was used at indicated concentrations.
Protein expression
For total lysates the cellular pellet was resuspended in Laemmli,
boiled, and sonicated. Low molecular weight protein NOXA was
detected by Western blotting according to Schaegger and von
Jagow [53]. Western blot was performed using following
antibodies: anti-ATR, anti-p53 (Santa Cruz, USA), anti-ATM,
anti-DNAPK, anti-(Lys382)p53, anti-(Ser15)p53, anti-(Ser20)p53
(Cell Signaling, USA), anti-NOXA (Calbiochem, USA), anti-
PUMA (Abcam, UK), anti-p21 (BD Pharmingen, USA), anti-
GAPDH (Biodesign, USA); anti-b-actin (Sigma, Germany). FAS
was detected by FACS analysis using FITC conjugated anti-FAS
antibody (NatuTec, Germany).
mRNA Expression
Total RNA was extracted and cDNA prepared according to
standard protocols. Expression analysis was done using equal
amounts of cDNA and primer pairs as described in table 1. The
relative amount of synthesized cDNA was determined through
RT-qPCR (7500 Fast Real-Time PCR System or 7900HT Fast
Real-Time PCR System, Applied Biosystems, USA).
MTT assay
IC50 in different cell lines upon cisplatin was determined by
MTT assay as described previously [54].
Apoptosis
Apoptosis was assessed by FITC-conjugated Annexin-V staining
(Pharmingen, USA) as described [55].
siRNA experiments
For silencing we used siGenome SMARTpool siRNA (Dhar-
macon, UK). Sequences targeted by SMARTpool siRNAs are
described in table 2. As a control we used siGenome Non-
Table 1. Primer pairs used for RT-qPCR.
gene sense antisense
FAS 59-TGGACCCTCCTACCTCTGGTTCT-39 59-GCAGGGCACGCAGTCTGGTT-39
GAPDH 59-AGCCTCAAGATCATCAGCAATG-39 59-CACGATACCAAAGTTGTCATGGAT-39
NOXA 59-GCAGAGCTGGAAGTCGAGTGT-39 59-AAGTTTCTGCCGGAAGTTCAG-39
p21 59-GGCAGACCAGCATGACAGATT-39 59-GCGGATTAGGGCTTCCTCTT-39
PUMA 59-ACGACCTCAACGCACAGTACG-39 59-TCCCATGATGAGATTGTACAGGAC-39
BAX 59-ACCAAGAAGCTGAGCGAGTGT-39 59-ACAAACATGGTCACGGTCTGC-39
doi:10.1371/journal.pone.0019198.t001
Table 2. siRNA target sequences.
gene siRNA1 siRNA2 siRNA3 siRNA4
ATM GCAAAGCCCUAGUAACAUA GGGCAUUACGGGUGUUGAA UCGCUUAGCAGGAGGUGUA UGAUGAAGAGAGACGGAAU
ATR GAACAACACUGCUGGUUUG GCAACUCGCCUAACAGAUA UCUCAGAAGUCAACCGAUU GAAUUGUGUUGCAGAGCUU
FAS UAGAUGAGAUCAAGAAUGA GAAAGAAGCGUAUGACACA GCUGGAGUCAUGACACUAA GUUCAACUGCUUCGUAAUU
NOXA AAACUGAACUUCCGGCAGA AAUCUGAUAUCCAAACUCU CUGGAAGUCGAGUGUGCUA GCAAGAACGCUCAACCGAG
p53 GAGGUUGGCUCUGACUGUA GCACAGAGGAAGAGAAUCU GAAGAAACCACUGGAUGGA GCUUCGAGAUGUUCCGAGA
PUMA CGGACGACCUCAACGCACA CCGAGAUGGAGCCCAAUUA CCUGGAGGGUCCUGUACAA GGCGGAGACAAGAGGAGCA
DNAPK GCAAAGAGGUGGCAGUUAA GAGCAUCACUUGCCUUUAA GAUGAGAAGUCCUUAGGUA GCAGGACCGUGCAAGGUUA
doi:10.1371/journal.pone.0019198.t002
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using DharmaFECT#3 (Dharmacon, UK). 48 h after transfection
cells were treated according to requirements. To evaluate the
efficacy of siRNA silencing protein lysates were obtained and
analyzed by Western Blot.
Microarray analysis
Microarray analysis was performed by Microarray Facility
Tu ¨bingen, Germany. To assess global gene expression, Human
Gene 1.1 ST Array Plate (Affymetrix, USA) was used. Data was
obtained from three independent experiments per treatment. In
order to examine gene expression prior to induction of apoptosis,
cells were treated with Cisplatin for 6 h before they were harvested
and RNA was extracted. Microarray data are MIAME compliant
and were deposited in the ArrayExpress database (www.ebi.ac.uk/
arrayexpress) under accession number E-MTAB-410.
Statistics
Data are expressed as standard deviation of the means (SD).
Changes in paired samples were analyzed using two-sided paired t-
Test.
Supporting Information
Figure S1 Hypersensitivity of 2102EP to Cisplatin is
dependent on p53. siRNA-mediated knockdown of p53 rescues
2102EP cells from Cisplatin-induced apoptosis. Cells were
transfected with siRNA and incubated for 48 h prior to Cisplatin
treatment (16 h). Left panel: verification of p53 knockdown by
Western Blot. Middle and right panel: cells were stained with
Annexin-V/FITC and PI and analyzed by flow cytometry. Graph
reflects means 6SD of survival after Cisplatin relating to
corresponding controls from 3 experiments (P=0.0018).
(TIF)
Figure S2 NTERA are characterized by low levels of p21
transcript and protein both constitutively as well as
upon Cisplatin treatment. (A) comparison of p21 transcript
levels in NTERA-2D1 and primary fibroblasts isolated from
human lung tissue cultivated in presence or absence of Cisplatin
for 8 h. (B) comparison of p53 and p21 protein levels in NTERA-
2D1 and lymphocytes cultivated in presence or absence of
indicated time periods.
(TIF)
Figure S3 NOXA and PUMA are important mediators of
Cisplatin-induced apoptosis in 2102EP cells. Cells were
transfected with siRNA and incubated for 48 h prior to Cisplatin
treatment (16 h). Upper panel: validation of siRNA efficacy by
Western Blot (for NOXA and PUMA; upper left panels) or by
evaluation of surface expression using a CD95/FAS specific
antibody conjugated to FITC and flow cytometry (for FAS; upper
right panel). Lower panel: cell survival upon Cisplatin treatment.
Cells were stained with Annexin-V/FITC and PI and analyzed by
flow cytometry. Graph reflects means 6SD of survival after
Cisplatin relating to corresponding controls from 3 experiments
(*: P,0.05).
(TIF)
Figure S4 2102EP cells are sensitive to pro-apoptotic
functions of p53 independent of DNA damage. (A) p53 is
accumulated upon Cisplatin, Nutlin, and Bortezomib in 2102EP
cells. Cells were treated with Cisplatin, Nutlin-3, or Bortezomib,
respectively for 16 h and p53 protein was analyzed by Western
Blot. (B) Apoptosis upon the non-genotoxic agents Nutlin-3 and
Bortezomib is dependent on p53. Cells were transfected with
siRNA and cultivated for 48 h prior to Nutlin-3 or Bortezomib
treatment (16 h). Cells were stained with Annexin-V/FITC and PI
and analyzed by flow cytometry.
(TIF)
Figure S5 NTERA cells are capable to remove DNA-Pt
adducts from DNA: (A) zVADfmk almost completely blocks
Cisplatin-induced cell death in NTERA-2D1 cells. Cells were pre-
treated with zVADfmk for 2 h prior to Cisplatin. After 24 h cell
death was quantified using Annexin-V/PI staining. (B) NTERA
cells were pre-treated with 50 mM zVADfmk to inhibit caspase
activation for 2 h and then incubated with 30 mM Cisplatin for
another 2 h. Cells were then washed and incubated in fresh
medium containing zVADfmk for indicated time period before
harvesting. Upper panel: DNA adducts were quantified as
described (Liedert et al., 2006*). Lower panel: DNA was isolated
and platinum was quantified by inductively-coupled-plasma mass-
spectrometry (ICP MS). *: Liedert B, Pluim D, Schellens J,
Thomale J (2006). Adduct-specific monoclonal antibodies for the
measurement of cisplatin-induced DNA lesions in individual cell
nuclei. Nucleic Acids Res 34: e47.
(TIF)
Table S1 p53 targets regulated by Cisplatin: Differenti-
ated and control cells were treated with Cisplatin for 6 h, RNA
was isolated and applied to microarray analysis to assess global
gene expression. Table shows p53 targets changed at least 1.5 fold
upon Cisplatin treatment of undifferentiated cells.
(DOC)
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